Ultragenyx Pharmaceutical
RARE
161 hedge funds and large institutions have $2.35B invested in Ultragenyx Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 71 increasing their positions, 53 reducing their positions, and 30 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 171 → 161 (-10)
12% less call options, than puts
Call options by funds: $9.27M | Put options by funds: $10.5M
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
41% less capital invested
Capital invested by funds: $3.98B → $2.35B (-$1.63B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$120M |
| 2 |
State Street
Boston,
Massachusetts
|
+$19.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$19.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.82M |
| 5 |
O
OrbiMed
New York
|
+$8.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.1M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$14.3M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
-$13M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$12.9M |
| 5 |
Jennison Associates
New York
|
-$11.2M |
RARE Hedge Fund Activity: Q1 2016 in Review
161 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2016, worth a combined $2.35B — down 41% from $3.98B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of RARE and 22 opened new positions — a net loss of 8 holders — while 53 trimmed existing stakes and 71 added.
The largest buyer was Wellington Management Group, adding an estimated $120M. The largest seller was Ameriprise, cutting an estimated $17.1M.
- 161 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2016, down from 171 in Q4 2015.
- Funds reported $2.35B of Ultragenyx Pharmaceutical stock for Q1 2016, down 41% quarter-over-quarter.
- 22 funds opened new Ultragenyx Pharmaceutical positions in Q1 2016 and 30 closed out, a net change of -8 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2016 was Wellington Management Group, an estimated $120M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2016 was Ameriprise, an estimated $17.1M sold.
Based on aggregated 13F filings for Q1 2016.